United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU In a landmark decision, the European Commission (EC) has authorized Biogen Inc.’s SKYCLARYS (omaveloxolone) for the treatment of… byPallavi MadhirajuFebruary 13, 2024